In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline. Masimo CEO waives right to $600 million payout in fight with activist investor Masimo Corp Chief Executive Joe Kiani has waived his rights for roughly $600 million in special payment if the U.S. medical device maker appoints a lead independent director, the company said on Thursday.